よむ、つかう、まなぶ。
08参考資料１ ヒトパピローマウイルス（HPV）ワクチンファクトシート追補版 (66 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_63875.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第31回 9／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus
(types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young
adult women. Pediatrics. 2006;118(5):2135-45.
42.
Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety
and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1
virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr
Infect Dis J. 2007;26(3):201-9.
43.
Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, et al. 4-
Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10
Years. Pediatrics. 2017;140(6).
44.
Mikamo H, Yamagishi Y, Murata S, Yokokawa R, Han SR, Wakana A, et al. Efficacy,
safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase
3, placebo-controlled study. Vaccine. 2019;37(12):1651-8.
45.
Murata S, Takeuchi Y, Yamanaka K, Hayakawa J, Yoshida M, Yokokawa R, et al. Safety
and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label
Study. Jpn J Infect Dis. 2019;72(5):299-305.
46.
Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, et al.
Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the
Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. J Infect Dis. 2016;214(8):1276-83.
47.
Parker KH, Kemp TJ, Isaacs-Soriano K, Abrahamsen M, Pan Y, Lazcano-Ponce E, et al.
HPV-specific antibodies at the oral cavity up to 30 months after the start of vaccination with the
quadrivalent HPV vaccine among mid-adult aged men. Vaccine. 2019;37(21):2864-9.
48.
Castellsagué X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, et al.
Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892-901.
49.
Moreira ED, Jr., Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, et al. Safety
Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials.
Pediatrics. 2016;138(2).
50.
Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, et al.
Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics. 2015;136(1):e28-39.
51.
Ruiz-Sternberg Á M, Moreira ED, Jr., Restrepo JA, Lazcano-Ponce E, Cabello R, Silva
A, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin
American girls, boys, and young women. Papillomavirus Res. 2018;5:63-74.
52.
Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, et al. Long-term
immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls
and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res.
2020;10:100203.
66
(types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young
adult women. Pediatrics. 2006;118(5):2135-45.
42.
Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety
and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1
virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr
Infect Dis J. 2007;26(3):201-9.
43.
Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, et al. 4-
Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10
Years. Pediatrics. 2017;140(6).
44.
Mikamo H, Yamagishi Y, Murata S, Yokokawa R, Han SR, Wakana A, et al. Efficacy,
safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase
3, placebo-controlled study. Vaccine. 2019;37(12):1651-8.
45.
Murata S, Takeuchi Y, Yamanaka K, Hayakawa J, Yoshida M, Yokokawa R, et al. Safety
and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label
Study. Jpn J Infect Dis. 2019;72(5):299-305.
46.
Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, et al.
Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the
Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. J Infect Dis. 2016;214(8):1276-83.
47.
Parker KH, Kemp TJ, Isaacs-Soriano K, Abrahamsen M, Pan Y, Lazcano-Ponce E, et al.
HPV-specific antibodies at the oral cavity up to 30 months after the start of vaccination with the
quadrivalent HPV vaccine among mid-adult aged men. Vaccine. 2019;37(21):2864-9.
48.
Castellsagué X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, et al.
Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892-901.
49.
Moreira ED, Jr., Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, et al. Safety
Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials.
Pediatrics. 2016;138(2).
50.
Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, et al.
Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics. 2015;136(1):e28-39.
51.
Ruiz-Sternberg Á M, Moreira ED, Jr., Restrepo JA, Lazcano-Ponce E, Cabello R, Silva
A, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin
American girls, boys, and young women. Papillomavirus Res. 2018;5:63-74.
52.
Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, et al. Long-term
immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls
and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res.
2020;10:100203.
66